Skip to main content

Redmile Group, LLC's Form 4 filing

IGM Biosciences, Inc. (IGMS) · filed Jul 3, 2023

Accession no.
0001104659-23-077730
Filed
Jul 3, 2023, 9:45 PM ET
Trade date
Jun 29-30, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions. Open-market purchases total $757.6K. Open-market sales total $757.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Redmile Group, LLCCIK 0001425738Director
Green JeremyCIK 0001650527Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 29, 2023Common StockSSaleDisposed−80,423$9.42−$757,584.662,893,763Indirect
Jun 29, 2023Common StockPPurchaseAcquired+80,423$9.42+$757,584.662,974,186Indirect
Jun 29, 2023Common StockJOtherDisposed−54,740$9.42−$515,650.82,919,446Indirect
Jun 29, 2023Common StockJOtherAcquired+54,740$9.42+$515,650.82,974,186Indirect
Jun 30, 2023Common StockAGrant or awardAcquired+492$0.00$02,974,678Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)